Search - tctmd.com

Displaying 21 - 40 of 135

Sort: Relevancy | Date

Presentation CACI 2019

¿Qué papel juegan actualmente los nuevos anticoagulantes en la prevención del stroke?

Presenter: Nicolás Gonzalez

November 29, 2019

Presentation TCT 2019

Don't Forget Anticoagulant Therapy!

Presenter: Sanjit Jolly

September 27, 2019

Presentation SIF 2019

Fundamentals of Pharmacology: What You Need to Know as an Interventionalist

Presenter: Sripal Bangalore

March 27, 2019

Presentation

Continued vs Interrupted Oral Anticoagulation During Transfemoral TAVR and Impact of Postop Anticoagulant Management in A-fib Patients

January 09, 2019

Presentation TCT 2018

Adjunctive Pharmacology Following LAA Closure in Anticoagulant Indicated and Contraindicated Patients

Presenter: James B. Hermiller Jr, David Hildick-Smith, Martin W. Bergmann

September 24, 2018

Presentation TCT 2018

Debate: Is LAA Closure a Valid Alternative for Patients with No or Mild Contraindications to Anticoagulants? Yes - LAA Closure Reduces Hemorrhagic Stroke and Mortality And Nearly Everyone Has a Reason Not to Take Oral Anticoagulants!

Presenter: James B. Hermiller Jr, David Hildick-Smith, David R. Holmes Jr.

September 24, 2018

Presentation TCT 2018

Debate: Is LAA Closure a Valid Alternative for Patients With No or Mild Contraindications to Anticoagulants? No NOACs Are Strongly Preferred to LAA Closure!

Presenter: James B. Hermiller Jr, David Hildick-Smith, Freek W.A. Verheugt

September 24, 2018

Presentation TCT 2018

Consensus: Considerations In The High Bleeding Risk Patient Requiring PCI And Oral Anticoagulant Therapy

Presenter: George D. Dangas, Giuseppe Tarantini, Roxana Mehran

September 23, 2018

Presentation TCT 2018

Case #1 Introduction: A High Bleeding Risk Patient With Afib And ACS Requiring PCI And Oral Anticoagulant Therapy

Presenter: George D. Dangas, Giuseppe Tarantini, Steven R. Bailey, Giovanni Esposito, Juan F. Granada, Roxana Mehran, Francesco Saia

September 23, 2018

Presentation TCT 2018

Case Presentation: Chronic Oral Anticoagulant and Antiplatelet Management Decisions

Presenter: Walter Desmet, Guy J. Friedrich, Kurt Huber, Eduard Margetic, Oleg Polonetsky

September 22, 2018

Presentation The Structural Heart Disease Summit 2018

Updated Amulet Outcomes and Ongoing Studies in Anticoagulant Indicated and Contraindicated Patients

Presenter: William A. Gray, Gregg W. Stone, DJ Lakkireddy

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Updated Watchman Results in Anticoagulant Indicated and Contraindicated Patients: Randomized Trials and Registries

Presenter: William A. Gray, Gregg W. Stone, Matthew J. Price

June 22, 2018

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticouagulants

Presentation ACC 2018

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticoagulants

Presenter: Steve Deitelzweig

March 12, 2018

Presentation TCT 2017

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Presenter: Samir R. Kapadia, David J. Moliterno

November 01, 2017

Presentation TCT 2017

When and Which Antiplatelet Agent Should Be Dropped When Using Oral Anticoagulant Therapy?

Presenter: Robert A. Harrington, Kurt Huber, Roxana Mehran

November 01, 2017

Presentation TCT 2017

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

Presenter: Robert A. Harrington, Kurt Huber, Michelle O'Donoghue

November 01, 2017

Presentation TCT 2017

What Is (and Is Not) Known About DAPT Decisions in Patients on Chronic Oral Anticoagulants

Presenter: Robert A. Harrington, Kurt Huber, Freek W.A. Verheugt

November 01, 2017

Presentation TCT 2017

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus Antiplatelet Therapy

Presenter: Robert A. Harrington, Kurt Huber, Renato D. Lopes

November 01, 2017

Presentation TVT 2017

The Latest in TAVR Adjunctive Pharmacotherapy: The Case for Routine vs Selective Anticoagulant Therapy

Presenter: Martin B. Leon, Hendrik Treede, George D. Dangas

June 16, 2017

Presentation

CLOSE: Closure of PFO, Oral Anticoagulants, or Antiplatelet Therapy to Prevent Stroke Recurrence

May 24, 2017

Advertisement

¿Qué papel juegan actualmente los nuevos anticoagulantes en la prevención del stroke?

Don't Forget Anticoagulant Therapy!

Fundamentals of Pharmacology: What You Need to Know as an Interventionalist

Continued vs Interrupted Oral Anticoagulation During Transfemoral TAVR and Impact of Postop Anticoagulant Management in A-fib Patients

Adjunctive Pharmacology Following LAA Closure in Anticoagulant Indicated and Contraindicated Patients

Debate: Is LAA Closure a Valid Alternative for Patients with No or Mild Contraindications to Anticoagulants? Yes - LAA Closure Reduces Hemorrhagic Stroke and Mortality And Nearly Everyone Has a Reason Not to Take Oral Anticoagulants!

Debate: Is LAA Closure a Valid Alternative for Patients With No or Mild Contraindications to Anticoagulants? No NOACs Are Strongly Preferred to LAA Closure!

Consensus: Considerations In The High Bleeding Risk Patient Requiring PCI And Oral Anticoagulant Therapy

Case #1 Introduction: A High Bleeding Risk Patient With Afib And ACS Requiring PCI And Oral Anticoagulant Therapy

Case Presentation: Chronic Oral Anticoagulant and Antiplatelet Management Decisions

Updated Amulet Outcomes and Ongoing Studies in Anticoagulant Indicated and Contraindicated Patients

Updated Watchman Results in Anticoagulant Indicated and Contraindicated Patients: Randomized Trials and Registries

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticoagulants

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

When and Which Antiplatelet Agent Should Be Dropped When Using Oral Anticoagulant Therapy?

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

What Is (and Is Not) Known About DAPT Decisions in Patients on Chronic Oral Anticoagulants

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus Antiplatelet Therapy

The Latest in TAVR Adjunctive Pharmacotherapy: The Case for Routine vs Selective Anticoagulant Therapy

CLOSE: Closure of PFO, Oral Anticoagulants, or Antiplatelet Therapy to Prevent Stroke Recurrence

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content